Biotage AB Nomination Committee

Biotage AB Nomination Committee

A Nomination Committee consisting of shareholder representatives and the
Chairman of the Board of Directors has been formed for Biotage AB. The
Nomination Committee shall, before the Annual General Meeting 2008, prepare
proposals for the election of Chairman and other members of the Board of
Directors, the election of auditors, the election of Chairman of the Annual
General Meeting, the determination of fees and matters pertaining thereto

The members of the Nomination Committee are: 
Björn Odlander, HealthCap 
Karl Swartling, Investor Growth Capital
Carl Rosén, 2 AP-fonden 
Ove Mattsson, Chairman of the Board

Shareholders wishing to submit a proposal for members of the Board of Directors
may do so by contacting to the Chairman of the Board of Directors of Biotage AB
at info@eu.biotage.com. 

Contact:
Torben Jörgensen, President and CEO
Tel: +46 707 49 05 84, torben.jorgensen@eu.biotage.com

About Biotage 
Biotage is a global company active in life science research with strong
technologies, a broad range of operations and a long-term view of the market.
The company offers solutions, knowledge and experience in the areas of genetic
analysis and medicinal chemistry. In 2005 operations and products were acquired
from the American company Argonaut, further strengthening the medicinal
chemistry product range. The customers include the worlds top 30 pharmaceutical
companies, the worlds top 20 biotech companies, and leading academic institutes.
The company is headquartered in Uppsala and has offices in the U.S., Japan, UK,
Germany and several other European countries. Biotage has 332 employees and had
sales of 520 MSEK in 2006. Biotage is listed on the OMX Nordic Exchange
Stockholm AB. Website: www.biotage.com